Abstract

Treatment of hyperuricemia with allopurinol and Febuxotate has been shown to be effective in hypertensive patients. Studies comparing the effects of both drugs in hypertensive patients were very limited, especially in the Vietnam population. Evaluating the treatment outcome of febuxostat when compared with allopurinol in hyperuricemia patients with hypertension in Vietnam. We conducted a randomized controlled clinical trial with an allocation ratio of 1:2 on 108 hyperuricemia outpatients with hypertension ≥40 years old. Group A was treated with allopurinol 100 mg, increased to 300 mg if treatment results were not achieved. Group B used febuxostat 40 mg, which increased to 80 mg. The endpoint was to control serum uric acid levels

Key words: hyperuricemia, hypertension, randomized controlled clinical trial, febuxostat, allopurinol.